Company news
Sandoz Group Ltd (SIX:SDZ) news
Every Sandoz Group Ltd press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Sandoz announces collaboration with mAbxience to expand patient access to life-enhancing biosimilar medicines
September 18, 2026
Sandoz issues EUR 500 million bond
September 14, 2026
Sandoz invests in new drug substance facility in Ljubljana, Slovenia, to expand biosimilar manufacturing capacity
September 8, 2026
Sandoz announces strategic collaboration with Henlius on up to 10 biosimilars, further expanding industry-leading pipeline
August 16, 2026
Sandoz delivers strong H1 2026 results, with outstanding biosimilar growth in the second quarter
August 5, 2026
Sandoz takes further steps to resolve legacy US generic medicine litigation
August 3, 2026
Sandoz confirms regulatory approval for new semaglutide treatment option in Brazil, paving way to expand patient access
July 29, 2026
Sandoz announces key leadership changes
July 15, 2026
Sandoz moves up Swiss equity rankings to join premier Swiss Market Index
July 9, 2026
Sandoz to Host Capital Markets Day: Maximising Sandoz Value in Its Golden Decade for Biosimilars
June 22, 2026
Sandoz steps up in-house biosimilar capabilities, opening state-of-the-art development centre to capture ‘golden decade’ opportunity
June 17, 2026
Sandoz marks 80 years of antibiotics with call for urgent political action to safeguard European medicine security
May 28, 2026
Sandoz confirms European Commission approval for biosimilars Bysumlog® (insulin lispro) and Dazparda® (insulin aspart), strengthening position in diabetes
May 15, 2026
Sandoz reports strong biosimilars growth in Q1 2026; full-year 2026 guidance confirmed
April 29, 2026
Sandoz signs landmark agreement with Rwandan government to ensure stable provision of critical medicines across selected African markets
April 15, 2026
Shareholders approve all resolutions proposed by Board of Directors at 2026 Annual General Meeting of Sandoz Group AG
April 9, 2026
Sandoz : Q1 - (260401 Sandoz Aide Memoire)
April 2, 2026
Samsung Bioepis Enters into Partnership Agreement with Sandoz for Up to Five Next-Generation Biosimilar Candidates
March 18, 2026
Sandoz issues CHF 550 million in bonds and extends its USD 2 billion revolving credit facility by one year
March 11, 2026
Sandoz creates new global biosimilar development, manufacturing and supply unit, appoints industry veteran Armin Metzger to lead next phase of growth
March 10, 2026
Sandoz delivers strong full-year results; guidance for 2026 reflects an expected acceleration in growth
February 25, 2026
Sandoz confirms European Commission approval for Ranluspec® (ranibizumab), further strengthening overall biosimilars leadership and position in ophthalmology
February 23, 2026
Sandoz receives US FDA approval to expand Enzeevu® (aflibercept-abzv) label for multiple retinal indications
February 18, 2026
Sandoz Canada launches first ophthalmology biosimilar
February 2, 2026
Sandoz confirms European Commission approval of Ondibta® (insulin glargine), strengthening overall biosimilars leadership and position in diabetes
January 14, 2026
Sandoz CEO, Speaking at 44th Annual J.P. Morgan Healthcare Conference, Will Outline Plans to Capitalize on Unprecedented Golden Decade of Affordable Medicines Opportunity
January 12, 2026
Polpharma Biologics Confirms U.S. Launch of Tyruko® (natalizumab), the First and Only Biosimilar for Multiple Sclerosis
November 17, 2025
In A Landmark Industry Transaction, Evotec Signs Agreement With Sandoz, Resulting In Payments Potentially Over US $650 M Plus Royalties
November 4, 2025
Sandoz Canada launches PrSandoz® Sacubitril-Valsartan, expanding access to heart failure treatments
October 1, 2025
Sandoz launches affordable iron sucrose injection for treatment of iron deficiency anemia in patients with chronic kidney disease in US
September 24, 2025
Sandoz welcomes Quebec government support for Boucherville plant modernization project
August 27, 2025
Sandoz launches renewable energy partnership to cover nearly 90% of electricity demand for European operations
August 12, 2025
Sandoz delivers strong H1 2025 results, with accelerated sales growth in the second quarter
August 7, 2025
Sandoz signs non-binding term sheet with Evotec SE to acquire its Just-Evotec Biologics in-house development and manufacturing capabilities in Toulouse, France
July 30, 2025
Sandoz further asserts leadership in biosimilars, breaking ground on new Slovenia facility to expand European biosimilar hub and global market reach
July 1, 2025
Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]
June 2, 2025
Sandoz launches Pyzchiva® autoinjector, first commercially available in Europe for ustekinumab biosimilars
May 21, 2025
Sandoz reports Q1 2025 net sales in line with company expectations; full-year guidance confirmed
April 30, 2025
Sandoz enters global collaboration license agreement with Henlius to commercialize leading oncology therapy, ipilimumab, in multiple indications
April 29, 2025
Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG
April 15, 2025
[Corrected] Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US
April 14, 2025
Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US
April 14, 2025
Sandoz strengthens its balance sheet by issuing new bonds to repay spin-off term loans, and signs new USD 2 billion revolving credit facility
March 31, 2025
Sandoz reports strong FY 2024 results and Q4 2024 sales
March 5, 2025
Sandoz launches biosimilar Pyzchiva® (ustekinumab-ttwe) in the US, offering new treatment for around 12 million patients[1-4]
February 24, 2025